Several other equities research analysts also recently commented on INGN. ValuEngine raised Inogen from a hold rating to a buy rating in a report on Tuesday, January 7th. JPMorgan Chase & Co. increased their price objective on Inogen from $47.50 to $60.00 and gave the company an underweight rating in a report on Friday, December 20th. Finally, Needham & Company LLC reissued a buy rating and issued a $90.00 price objective on shares of Inogen in a report on Friday, November 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $80.00.
Shares of NASDAQ INGN traded up $0.61 during trading hours on Wednesday, hitting $51.70. The company had a trading volume of 9,541 shares, compared to its average volume of 353,076. The stock has a market capitalization of $1.11 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 3.70 and a beta of 1.63. The company has a quick ratio of 5.11, a current ratio of 5.79 and a debt-to-equity ratio of 0.01. Inogen has a 1-year low of $41.19 and a 1-year high of $155.75. The firm’s 50 day moving average is $68.51 and its 200-day moving average is $58.04.
Institutional investors have recently made changes to their positions in the business. Synovus Financial Corp acquired a new stake in Inogen during the 3rd quarter valued at $77,000. Steward Partners Investment Advisory LLC lifted its holdings in Inogen by 16.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the medical technology company’s stock valued at $100,000 after purchasing an additional 300 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Inogen by 235.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,243 shares of the medical technology company’s stock valued at $283,000 after purchasing an additional 2,980 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Inogen during the second quarter worth $315,000. Finally, Municipal Employees Retirement System of Michigan lifted its holdings in shares of Inogen by 65.0% during the third quarter. Municipal Employees Retirement System of Michigan now owns 5,460 shares of the medical technology company’s stock worth $262,000 after buying an additional 2,150 shares in the last quarter.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: S&P 500 Index
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.